We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

149 hedge funds and large institutions have $685M invested in Ocular Therapeutix in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.1M

69% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 35

1.29% more ownership

Funds ownership: 62.11% → 63.4% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3% less funds holding

Funds holding: 154 → 149 (-5)

12% less capital invested

Capital invested by funds: $774M → $685M (-$89.5M)

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

Holders
149
Holders Change
-5
Holders Change %
-3.25%
% of All Funds
2.59%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
23
Increased
59
Reduced
35
Closed
28
Calls
$24.5M
Puts
$11.1M
Net Calls
+$13.3M
Net Calls Change
+$12.2M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$27M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.4M
3
KCM
Kornitzer Capital Management
Kansas
+$8.53M
4
AS
Altshuler Shaham
Israel
+$8.22M
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.21M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$23.4M
2
BlackRock
BlackRock
New York
-$13.5M
3
CM
Castleark Management
Illinois
-$7.97M
4
Wells Fargo
Wells Fargo
California
-$7.04M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$5.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
26
Ikarian Capital
Texas
$5.95M – – –
Renaissance Technologies
27
Renaissance Technologies
New York
$4.64M +$4.21M +277,222 +556%
N
28
Nuveen
North Carolina
$3.7M +$87.5K +5,757 +2%
ACM
29
Altium Capital Management
New York
$3.63M -$1.06M -70,022 -21%
AAA
30
Affinity Asset Advisors
New York
$3.54M +$342K +22,500 +10%
Charles Schwab
31
Charles Schwab
California
$3.54M +$108K +7,128 +3%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$3.51M -$148K -9,753 -4%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$3.1M -$599K -39,412 -15%
NA
34
Nottingham Advisors
New York
$2.75M – – –
First Trust Advisors
35
First Trust Advisors
Illinois
$2.72M +$2.43M +159,739 +497%
LCG
36
Lisanti Capital Growth
New York
$2.55M -$230K -15,100 -8%
Citadel Advisors
37
Citadel Advisors
Florida
$2.16M +$671K +44,169 +41%
EP
38
Eversept Partners
New York
$2.13M +$2.28M +150,000 New
Principal Financial Group
39
Principal Financial Group
Iowa
$2.06M +$1.76M +115,671 +392%
Swiss National Bank
40
Swiss National Bank
Switzerland
$2M +$38K +2,500 +2%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$1.5M +$65.4K +4,300 +4%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$1.5M -$65.4K -4,303 -4%
QP
43
Quilter Plc
United Kingdom
$1.39M – – –
Assenagon Asset Management
44
Assenagon Asset Management
Luxembourg
$1.38M +$17K +1,119 +1%
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
$1.38M +$1.16M +76,202 +367%
Brown Advisory
46
Brown Advisory
Maryland
$1.28M – – –
Invesco
47
Invesco
Georgia
$1.25M +$397K +26,146 +42%
AllianceBernstein
48
AllianceBernstein
Tennessee
$1.23M – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$1.21M +$24.2K +1,591 +2%
US Bancorp
50
US Bancorp
Minnesota
$1.17M -$3.01K -198 -0.2%
1
2
3 4 5

OCUL Hedge Fund Activity: Q2 2021 in Review

149 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2021, worth a combined $685M — down 12% from $774M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of OCUL and 23 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 59 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $27M. The largest seller was Victory Capital Management, cutting an estimated $23.4M.

  • 149 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2021, down from 154 in Q1 2021.
  • Funds reported $685M of Ocular Therapeutix stock for Q2 2021, down 12% quarter-over-quarter.
  • 23 funds opened new Ocular Therapeutix positions in Q2 2021 and 28 closed out, a net change of -5 holders.
  • The largest Ocular Therapeutix buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $27M added.
  • The largest Ocular Therapeutix seller in Q2 2021 was Victory Capital Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q2 2021.